Inhibikase Therapeutics, Inc.

Ownership Transactions Reported by 17 Insiders

Symbol
IKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3350 Riverwood Parkway Se, Suite 1900, Atlanta, GA

Insiders trading volume in the past year

Inhibikase Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Sands Capital Life Sciences Pulse Fund II, L.P. 10%+ Owner $24.4M Jun 6, 2025
Roberto Francesco Bellini Director $2M +$2M Jun 30, 2025
Christopher Cabell President & Head of R&D $1.7M Feb 21, 2025
Vincent Aurentz Director $1.29M Jun 30, 2025
Amit Munshi Director $709K +$500K +239% Jun 30, 2025
Arvind Kush Director $199K +$199K Jun 30, 2025
Joseph Frattaroli Cheif Financial Officer $38.5K Mar 1, 2023
David McIntyre Chief Financial Officer $14.1K Apr 14, 2025
Dennis N. Berman Director Jun 30, 2025
Roy Lester Freeman Director Feb 14, 2025
Gisele Dion Director Jul 16, 2024
Milton H. Werner President and CEO, Director Jan 21, 2025
Elizabeth G. O'Farrell Director Jun 24, 2022
Mark T. Iwicki Chief Executive Officer, Director Feb 21, 2025
David Canner Director Jun 30, 2025
Garth Lees-Rolfe Chief Financial Officer Jan 21, 2025
Paul C. Grint Director Jul 16, 2024

Recent Insider Transactions by Companies or Individuals for Inhibikase Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.